Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis

Trial Profile

Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 18 Feb 2017 Results (n=708) of a post hoc analysis according to asymptomatic or symptomatic disease status at baseline, presented at the 2017 Genitourinary Cancers Symposium.
    • 11 Oct 2016 Results of an exploratory analysis assessing the effects of concomitant denosumab on OS were presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results of an exploratory analyses assessing changes in alkaline phosphatase dynamics and overall survival presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top